FTC goes after pharma middlemen’s price hikes on ‘specialty’ drugs

The top three phar­ma­cy ben­e­fit man­agers hiked the prices of dozens of “spe­cial­ty” gener­ic drugs, some by more than 1,000% of their ac­qui­si­tion cost, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.